SG131944A1 - N3-substituted imidazopyridine-derivatives as c-kit inhibitors - Google Patents

N3-substituted imidazopyridine-derivatives as c-kit inhibitors

Info

Publication number
SG131944A1
SG131944A1 SG200702982-0A SG2007029820A SG131944A1 SG 131944 A1 SG131944 A1 SG 131944A1 SG 2007029820 A SG2007029820 A SG 2007029820A SG 131944 A1 SG131944 A1 SG 131944A1
Authority
SG
Singapore
Prior art keywords
derivatives
kit inhibitors
substituted imidazopyridine
imidazopyridine
substituted
Prior art date
Application number
SG200702982-0A
Other languages
English (en)
Inventor
Arlindo L Castelhano
Andrew Philip Crew
Han-Qing Dong
Radoslaw Laufer
An-Hu Li
Li Qiu
Smith Colin Peter Sambrook
Tao Zhang
Original Assignee
Osi Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osi Pharm Inc filed Critical Osi Pharm Inc
Publication of SG131944A1 publication Critical patent/SG131944A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Otolaryngology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG200702982-0A 2003-08-21 2004-08-16 N3-substituted imidazopyridine-derivatives as c-kit inhibitors SG131944A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US49677603P 2003-08-21 2003-08-21

Publications (1)

Publication Number Publication Date
SG131944A1 true SG131944A1 (en) 2007-05-28

Family

ID=34272515

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200702982-0A SG131944A1 (en) 2003-08-21 2004-08-16 N3-substituted imidazopyridine-derivatives as c-kit inhibitors

Country Status (20)

Country Link
EP (1) EP1658289B1 (es)
JP (1) JP2007502822A (es)
KR (1) KR20060119871A (es)
CN (1) CN1839132A (es)
AP (1) AP2006003552A0 (es)
AR (1) AR045388A1 (es)
AT (1) ATE425977T1 (es)
AU (1) AU2004268950A1 (es)
BR (1) BRPI0413740A (es)
CA (1) CA2536174A1 (es)
DE (1) DE602004020073D1 (es)
IL (1) IL173615A0 (es)
IS (1) IS8318A (es)
MX (1) MXPA06002019A (es)
MY (1) MY138737A (es)
NO (1) NO20060670L (es)
RU (1) RU2006108799A (es)
SG (1) SG131944A1 (es)
TW (1) TW200519111A (es)
WO (1) WO2005021544A2 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2672172C (en) 2006-12-22 2016-05-03 Astex Therapeutics Limited Bicyclic heterocyclic compounds as fgfr inhibitors
CN101679409B (zh) 2006-12-22 2014-11-26 Astex治疗学有限公司 双环杂环衍生化合物、其医药组合物和其用途
GB0625827D0 (en) * 2006-12-22 2007-02-07 Astex Therapeutics Ltd New compounds
GB0720038D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New compounds
GB0720041D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New Compounds
PT2303270T (pt) 2008-05-05 2017-08-25 Sanofi Sa Derivados fundidos do ácido ciclopentanocarboxílico substituídos por acilamino e sua utilização como produtos farmacêuticos
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
PT2308877E (pt) * 2008-08-05 2014-05-02 Daiichi Sankyo Co Ltd Derivados de imidazopiridin-2-ona
WO2010045276A2 (en) * 2008-10-16 2010-04-22 Cara Therapeutics, Inc. Azabenzimidazolones
US20120189641A1 (en) 2009-02-25 2012-07-26 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
US8465912B2 (en) 2009-02-27 2013-06-18 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099363A1 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
GB0906470D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
GB0906472D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
AR079022A1 (es) 2009-11-02 2011-12-21 Sanofi Aventis Derivados de acido carboxilico ciclico sustituidos con acilamino, su uso como productos farmaceuticos, composicion farmaceutica y metodo de preparacion
US8501770B2 (en) * 2009-12-30 2013-08-06 Arqule, Inc. Substituted imidazopyridinyl-aminopyridine compounds
WO2012149014A1 (en) 2011-04-25 2012-11-01 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
ES2579855T3 (es) * 2011-06-24 2016-08-17 Arqule, Inc. Compuestos de imidazopiridinil-aminopiridina sustituidos
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
CN105308036B (zh) 2012-12-21 2019-06-21 普莱希科公司 用于激酶调节的化合物和方法及其适应症
KR20160135234A (ko) * 2014-03-24 2016-11-25 아르퀼 인코포레이티드 3-(3-(4-(1-아미노시클로부틸)페닐)-5-페닐-3h-이미다조[4,5-ｂ]피리딘-2-일)피리딘-2-아민의 제조 방법
EP3942045A1 (en) 2019-03-21 2022-01-26 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4129603A1 (de) * 1991-09-06 1993-03-11 Thomae Gmbh Dr K Kondensierte 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
TW251284B (es) * 1992-11-02 1995-07-11 Pfizer
AU6966696A (en) 1995-10-05 1997-04-28 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
US5990146A (en) 1997-08-20 1999-11-23 Warner-Lambert Company Benzimidazoles for inhibiting protein tyrosine kinase mediated cellular proliferation
US6326379B1 (en) 1998-09-16 2001-12-04 Bristol-Myers Squibb Co. Fused pyridine inhibitors of cGMP phosphodiesterase
US6348032B1 (en) 1998-11-23 2002-02-19 Cell Pathways, Inc. Method of inhibiting neoplastic cells with benzimidazole derivatives
AU6762400A (en) 1999-08-12 2001-03-13 Cor Therapeutics, Inc. Inhibitors of factor xa
WO2001021634A1 (en) 1999-09-21 2001-03-29 Lion Bioscience Ag Benzimidazole derivatives and combinatorial libraries thereof
EP1255750A1 (en) 2000-02-01 2002-11-13 Millenium Pharmaceuticals, Inc. INDOLE AND BENZIMIDAZOLE INHIBITORS OF FACTOR Xa
WO2003020698A2 (en) * 2001-09-06 2003-03-13 Prochon Biotech Ltd. Protein tyrosine kinase inhibitors

Also Published As

Publication number Publication date
IL173615A0 (en) 2006-07-05
WO2005021544A2 (en) 2005-03-10
MXPA06002019A (es) 2006-05-31
CA2536174A1 (en) 2005-03-10
MY138737A (en) 2009-07-31
EP1658289A2 (en) 2006-05-24
NO20060670L (no) 2006-05-12
WO2005021544A3 (en) 2005-06-16
AR045388A1 (es) 2005-10-26
AU2004268950A1 (en) 2005-03-10
KR20060119871A (ko) 2006-11-24
TW200519111A (en) 2005-06-16
EP1658289B1 (en) 2009-03-18
IS8318A (is) 2006-02-21
BRPI0413740A (pt) 2006-10-24
AP2006003552A0 (en) 2006-04-30
RU2006108799A (ru) 2006-07-27
DE602004020073D1 (de) 2009-04-30
ATE425977T1 (de) 2009-04-15
JP2007502822A (ja) 2007-02-15
CN1839132A (zh) 2006-09-27

Similar Documents

Publication Publication Date Title
IL173616A0 (en) N-substituted pyrazolyl-amidyl-benzimidazolyl c-kit inhibitors
SG131944A1 (en) N3-substituted imidazopyridine-derivatives as c-kit inhibitors
IL173381A0 (en) 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors
IL173614A0 (en) N-substituted benzimidazolyl c-kit inhibitors
ZA200700181B (en) Aryl-pyridine derivatives as 11-beta-HSD1 inhibitors
HK1107348A1 (en) Indozolone derivatives as 11b-hsd1 inhibitors
AP2048A (en) Diazepinoindole derivatives as kinase inhibitors
SI2039685T1 (sl) Heterobiciklične spojine kot P38 inhibitorji
HK1091838A1 (en) Gfat inhibitors
IL172132A0 (en) Thienopyridone derivatives as kinase inhibitors
HK1131055A1 (en) Novel benzylamine derivatives as cetp inhibitors
AU2003271566A8 (en) Pyrrolopyrazines as kinase inhibitors
IL179398A0 (en) Dpp-ib inhibitors
EP1551801A4 (en) NOVEL GAMMA-LACTAMES AS INHIBITORS OF BETA-SECRETASE
ZA200510319B (en) 6-arylamino-5-cyano-4-pyrimidinones as PDE9a inhibitors
HK1101871A1 (en) Novel keto-oxadiazole derivatives as cathepsin inhibitors
HK1096968A1 (en) Aminopyridine-derivatives as inductible no-synthase inhibitors
IL182739A0 (en) Acylatednonadepsipeptides used as lysobactin derivatives
ZA200409686B (en) Bicyclic 6-aklylidene-penems as ?-lactamases inhibitors
IL164898A0 (en) Heterotricyclyl 6-alkylidene-penems as beta-lactamase inhibitors
GB0421355D0 (en) Inhibitors
GB0421356D0 (en) Inhibitors
AU2003232362A8 (en) 4-pyrazol-phenylalanine derivatives as ace-nep inhibitors
GB0318913D0 (en) Apoptosis inhibitors
GB0300607D0 (en) Inhibitors